Cost analysis for different sequential treatment regimens for metastatic renal cell carcinoma in China-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cost analysis for different sequential treatment regimens for metastatic renal cell carcinoma in China

Published:2018-09-10 Issue:12 Volume:21 Page:1150-1158
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Shi Guohai¹²,Park Sang Hee³,Ren Hongye⁴,Xue Mei³,Lu Xiaolin¹²,Dong Peng⁵,Gao Xin³

Affiliation:

1. Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, PR China;

2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, PR China;

3. Pharmerit International, Bethesda, MD, USA;

4. Pfizer Investment Co., Ltd, Shanghai, PR China;

5. Pfizer Investment Co., Ltd, Beijing, PR China

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2018.1515769

Reference53 articles.

1. Cancer statistics, 2013

2. Critical appraisal of sorafenib in the treatment of Chinese patients with renal cell carcinoma

3. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015

4. Global cancer statistics

5. Combination of surgery and immunotherapy in metastatic renal cell carcinoma

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Scoping review of economic analyses of rare kidney diseases;Kidney International Reports;2024-09

2. Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis;Expert Review of Pharmacoeconomics & Outcomes Research;2024-03-21

3. Cost-effectiveness analysis of immune checkpoint inhibitors for first-line treatment of advanced esophageal squamous cell carcinoma based on fractional polynomial network meta-analysis;2024-01-30

4. Sponsorship bias in published pharmacoeconomic evaluations of national reimbursement negotiation drugs in China: a systematic review;BMJ Global Health;2023-11

5. Cost-effectiveness analysis of toripalimab plus chemotherapy for patients with advanced esophageal squamous cell carcinoma in China;Expert Review of Pharmacoeconomics & Outcomes Research;2023-10-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3